<DOC>
	<DOC>NCT02339090</DOC>
	<brief_summary>The trial will compare a twice-monthly somavaratan dosing regimen for non-inferiority of treatment effect against daily injections of rhGH.</brief_summary>
	<brief_title>Versartis Long-Acting Growth Hormone in Children Compared to Daily rhGH</brief_title>
	<detailed_description>This study is designed as a pivotal study to compare the safety and efficacy of a selected dose regimen of somavaratan to daily rhGH. The study is a randomized, multi-center, open label study of 12 months duration. The primary endpoint is height velocity at 12 months.</detailed_description>
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Chronological Age ≥ 3.0 years and ≤ 10.0 (girls) and ≤ 11.0 (boys). Prepubertal status: Absent breast development in girls, testicular volume &lt; 4.0 mL in boys. Diagnosis of GHD as documented by two or more GH stimulation test results ≤ 10.0 ng/mL. Height SD score ≤ 2.0 at screening. Weight for Stature ≥ 10th percentile. IGFI SD score ≤ 1.0 at screening. Delayed bone age (≥ 6 months). Prior treatment with any growth promoting agent History of or concurrent significant disease (e.g. diabetes, cystic fibrosis, renal insufficiency). Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD) or confirmed diagnosis of a named syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder. Daily use of antiinflammatory doses of glucocorticoid. Prior history of leukemia, lymphoma, sarcoma or cancer. Treatment with an investigational drug in the 30 days prior to screening. Known allergy to constituents of the study drug formulation. Ocular findings suggestive of increased intracranial pressure and/or retinopathy at screening. Significant spinal abnormalities including scoliosis, kyphosis and spina bifida variants. Significant abnormality in screening laboratory studies</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>VRS-317</keyword>
	<keyword>Growth Hormone Deficiency</keyword>
	<keyword>Long Acting Recombinant Growth Hormone</keyword>
	<keyword>Long Acting Growth Hormone</keyword>
	<keyword>Pediatric Growth Hormone Deficiency</keyword>
	<keyword>Growth Hormone Replacement Therapy</keyword>
	<keyword>Versartis</keyword>
	<keyword>Xten</keyword>
	<keyword>Human Growth Hormone</keyword>
	<keyword>somavaratan</keyword>
	<keyword>growth failure</keyword>
</DOC>